title: Ciclopirox olamine lotion 1%: bioequivalence to ciclopirox olamine cream 1% and clinical efficacy in tinea pedis.
abstract: Studies were conducted to assess the bioequivalence of a new antimycotic formulation, ciclopirox olamine lotion 1%, to an established compound, ciclopirox olamine cream 1%. Results of in vitro studies, using skin samples from human cadavers and domestic pigs, demonstrated that the two formulations equally penetrate all layers of the stratum corneum and inhibit the growth of Trichophyton mentagrophytes and Candida albicans. In vivo studies in guinea pigs and in human volunteers demonstrated the comparable therapeutic efficacy of the lotion and the cream in experimental trichophytosis. In addition, a multicenter, double-blind clinical trial was undertaken to compare ciclopirox olamine lotion 1% with the vehicle alone in the treatment of patients with tinea pedis. Patients with plantar, interdigital, or vesicular tinea pedis were enrolled in the studies. Patients were treated for 28 days. Clinical and mycological responses were determined during treatment and two weeks posttreatment. Ciclopirox olamine lotion 1% was found to be significantly more effective than its vehicle in the treatment of patients with common tinea pedis. Minor localized side effects (pruritus, burning sensation) were reported in 2% of 89 patients treated with ciclopirox olamine lotion 1%. The results demonstrate the bioequivalence of ciclopirox olamine lotion 1% and ciclopirox olamine cream 1% and confirm the clinical effectiveness and safety of the lotion in the treatment of tinea pedis, a generally recalcitrant fungal infection. It is concluded that ciclopirox olamine lotion 1% can be used as an alternative to ciclopirox olamine cream 1% for treatment of tinea pedis, tinea versicolor, tinea cruris, tinea corporis, and cutaneous candidiasis when the convenience and/or cosmetic elegance of a lotion is desired.
authors.affiliation: Department of Dermatology, University of California School of Medicine, San Francisco.
authors.forename: R
authors.initials: R
authors.lastname: Aly
authors.forename: H I
authors.initials: HI
authors.lastname: Maibach
authors.forename: F K
authors.initials: FK
authors.lastname: Bagatell
authors.forename: W
authors.initials: W
authors.lastname: Dittmar
authors.forename: H
authors.initials: H
authors.lastname: Hänel
authors.forename: V
authors.initials: V
authors.lastname: Falanga
authors.forename: J J
authors.initials: JJ
authors.lastname: Leyden
authors.forename: H L
authors.initials: HL
authors.lastname: Roth
authors.forename: R B
authors.initials: RB
authors.lastname: Stoughton
authors.forename: I
authors.initials: I
authors.lastname: Willis
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000077768:Ciclopirox; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006168:Guinea Pigs; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D011728:Pyridones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011897:Random Allocation; D013552:Swine; D013810:Therapeutic Equivalency; D014008:Tinea Pedis / Q000188:drug therapy*; D014249:Trichophyton / Q000187:drug effects
chemical_list: D000935:Antifungal Agents; D011728:Pyridones; D000077768:Ciclopirox